The 2022 Tandem Meetings | Polatuzumab vedotin in patients with LBCL who have relapsed after CAR-T therapy
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the results of a retrospective study evaluating the safety and efficacy of the combination of polatuzumab vedotin plus rituximab with or without bendamustine in patients who have relapsed after standard of care (SOC) CAR-T therapy. In this study, no patients had to interrupt treatment due to toxicity, however, the efficacy was limited to patients with low tumor burden and the duration of response was relatively short. Polatuzumab vedotin may serve as a bridge to transplant or may have a role after progression on CAR-T therapy in the third-line setting. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
